Key result
Nifedipine-retard did not reduce the overall incidence of cardiac events compared to non-calcium channel blocker treatment in post-myocardial infarction patients.
Why the study?
Does nifedipine-retard reduce the occurrence of cardiac death or non-fatal myocardial infarction in post-MI patients treated with coronary thrombolysis?
Cohort (n=294)
No
Does nifedipine-retard reduce the occurrence of cardiac death or non-fatal myocardial infarction in post-MI patients treated with coronary thrombolysis?
Answers are grounded in this paper and cite their sources.
Retrospective analysis suggests that sustained-release nifedipine does not increase cardiac events in post-MI patients and may offer secondary prevention benefits in younger patients (<55 years) and non-smokers.
BACKGROUND: Calcium channel blockers (CCBs) may have a positive influence on the long-term prognosis of Japanese patients with ischemic heart disease. METHODS AND RESULTS: The effect of nifedipine-retard (NR) (n=202) compared with that of non-CCB treatment (n=92) on the secondary prevention of myocardial infarction (MI) was retrospectively investigated in patients who had survived acute MI between 1987 and 1996. The primary endpoint was the occurrence of cardiac death or non-fatal MI. The median follow-up was 6.3+/-2.4 years. The incidence of cardiac events was 8.9% in the NR group and 14.1% in the non-CCBs group (p=0.14, odds ratio (OR): 0.584, 95% confidence interval (CI): 0.286-1,193). However, subanalysis revealed that NR significantly reduced the incidence of cardiac events in patients aged less than 55 years (4.2 vs 18.2%, p=0.016, OR: 0.180, 95%CI: 0.045-0.721) and those who did not smoke (8.6 vs 16.4%, p=0.048, OR: 0.462, 95%CI: 0.203-0.999). CONCLUSION: Although this was a retrospective analysis, it showed that NR did not cause an increase in the incidence of cardiac events in post-MI patients; it even prevented cardiac events, especially in those who were less than 55 years of age and in non-smokers, suggesting the potential usefulness of CCBs in the secondary prevention of MI in Japan.
No takes yet. Share an insight, caveat, or question.
Tani et al. (2004) conducted a cohort in Acute myocardial infarction (secondary prevention) (n=294). Nifedipine-retard vs. Non-calcium channel blockers was evaluated on Occurrence of cardiac death or non-fatal myocardial infarction (OR 0.584, 95% CI 0.286-1.193, p=0.14). Nifedipine-retard did not reduce the overall incidence of cardiac events compared to non-calcium channel blocker treatment in post-myocardial infarction patients.
Synapse has enriched 10 related papers. Consider them for comparative context: